Exelixis (EXEL) Net Equity Issued and Repurchased (2011 - 2016)
Exelixis (EXEL) posted quarterly Net Equity Issued and Repurchased of $37000.0 for Q1 2016, down 99.97% quarter-over-quarter from $145.7 million in Q3 2015.
Exelixis (EXEL) Net Equity Issued and Repurchased (2011 - 2016) Analysis & Trends
Exelixis' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $37000.0 for Q1 2016.
- In Q1 2016, Net Equity Issued and Repurchased changed N/A year-over-year to $37000.0; the TTM figure through Mar 2016 stood at $145.7 million (up 4856366.67% YoY), while the FY2015 annual figure was $145.6 million, up 92.55% from the prior year.
- Net Equity Issued and Repurchased for Q1 2016 stood at $37000.0, down from $145.7 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $145.7 million in Q3 2015, with the low at -$3000.0 in Q4 2014.
- The 4-year median for Net Equity Issued and Repurchased is $32.5 million (2012), against an average of $47.7 million.
- Peak annual rise in Net Equity Issued and Repurchased reached 300.0% in 2012, while the deepest fall reached 63.77% in 2012.
- Exelixis' Net Equity Issued and Repurchased stood at $46000.0 in 2012, then sank by 106.52% to -$3000.0 in 2014, then surged by 4855133.33% to $145.7 million in 2015, then plunged by 99.97% to $37000.0 in 2016.
- Business Quant data shows EXEL's Net Equity Issued and Repurchased at $37000.0 in Q1 2016, $145.7 million in Q3 2015, and -$3000.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 37,000.00 |
| Mar 31, 2016 | 37,000.00 |
| Sep 30, 2015 | 145.65 Mn |
| Sep 30, 2015 | 145.65 Mn |
| Dec 31, 2014 | -3,000.00 |
| Dec 31, 2014 | -3,000.00 |
| Mar 31, 2014 | 75.65 Mn |
| Mar 31, 2014 | 75.65 Mn |
| Jun 30, 2012 | 46,000.00 |
| Jun 30, 2012 | 46,000.00 |
| Mar 31, 2012 | 64.99 Mn |
| Mar 31, 2012 | 64.99 Mn |
| Dec 31, 2011 | -2,000.00 |
| Dec 31, 2011 | -2,000.00 |
| Jun 30, 2011 | -23,000.00 |
| Jun 30, 2011 | -23,000.00 |
| Mar 31, 2011 | 179.40 Mn |
| Mar 31, 2011 | 179.40 Mn |